Immune Response to Pneumococcal Vaccination in HIV Infected Individuals

August 5, 2015 updated by: University of Toledo Health Science Campus
The purpose of the study. To characterize the immune response to the pneumococcal vaccine in HIV positive individuals and to dissect the most appropriate timing and frequency of vaccination.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

All potential study candidates will be asked to fill out a questionnaire concerning their medical history and medications. This survey will determine eligibility. If eligible, as part of the experimental protocol the HIV positive participants will agree to be randomized to immediate vs. delayed pneumococcal immunization and 3 blood draws around the time of immunization. The HIV negative control population will agree to immunization with pneumococcal polysaccharide vaccine (PPV), not standard of care for this population, and 3 blood draws around the time of immunization. The investigators will study the effect of pneumococcal vaccination in HIV positive adults. At the present time it is recommended that all HIV positive individuals receive the pneumococcal vaccine at the time of diagnosis with those with cluster of differentiation (CD4) count <200 to be vaccinated either immediately or alternatively, treated with highly active antiretroviral therapy (HAART) for 6 months followed by PPV. All patients are recommended to be re-vaccinated at 5 years. This is the standard of care. It is however unclear how the HIV positive patients respond to PPV. In the 1st part of the study, Part I, newly diagnosed HIV positive individuals will be recruited. As standard of care, these individuals will receive the pneumococcal vaccine regardless of their participation in this study. Those that agree to participate in the study will be grouped according to their CD4 count: >500, 200-500 or <200. Those with a CD4 count <200 will be randomly assigned to receive the vaccine immediately or to receive HAART for 6 months prior to vaccination, this is in accordance with the present recommendations, either immediate vaccination or giving HAART for 6 months prior to vaccination is considered acceptable.. Thus ALL HIV positive individuals will receive the vaccine as presently recommended. The HIV positive volunteers agree to (experimental part of the protocol):

  1. Be randomized to either immediate vaccination vs. 6 months after start of HAART if the CD4 count is <200
  2. Donate blood specimens at 3 different times: day 0, day of vaccination: 2 mL, at day 7, 40 mL and at day 28-42 a one time sample of 2 mL.
  3. Have their blood samples subjected to antibody analysis (concentration and functional activity) and antibody gene usage analysis There will be 4 HIV positive groups in this part of the study: CD4>500, CD4 200-500, CD4 < 200 immediate vaccination and CD4 <200, delayed vaccination.

There will be 19 individuals per group. The HIV negative controls in Part I of the study (n=19) who agree to participate will also be vaccinated with the pneumococcal vaccine. This is NOT a vaccine recommended for healthy adults but is NOT contra-indicated.

Thus as part of the experimental procedure for these individuals they will:

  1. Receive the FDA approved pneumococcal vaccine
  2. Blood samples will be obtained at day 0: 2 mL, day 7 40 mL and day 28-42, one time sample of 2 mL.
  3. Blood samples will be analyzed for antibody concentration, functional activity and gene family usage.

In summary, we will study a total of 5 groups in Part I:

Group 1: HIV positive CD4>500 Group 2: HIV positive CD4 200-500 Group 3: HIV positive CD4 < 200 immediate vaccination Group 4: HIV positive CD4<200 delayed (6 months) vaccination Group 5: HIV negative In part II of the study the investigators will evaluate the effect of a second pneumococcal vaccination, which is presently recommended, in HIV positive individuals, to be received 5 years after the first vaccination. Again, only those HIV positive individuals who are due for their second pneumovax will be asked to participate. They will be grouped according to their CD4 counts as CD4 >500 or CD4 200-500. Thus ALL HIV positive individuals will receive the vaccine as recommended.

The HIV positive volunteers solely agree to;

  1. Donate blood specimens at 3 different occasions: day 0, day of vaccination: 2 mL, at day 7, 40 mL and at day 28-42 a one time sample of 2 mL.
  2. Have their blood samples subjected to antibody analysis (concentration and functional activity) and antibody gene usage analysis There will be 2 HIV positive groups: CD4>500 and CD4 count 200-500. There will be 19 individuals per group.

The HIV negative controls in Part II of the study who agree to participate will be recruited from the population of individuals previously vaccinated with pneumovax. They will also be vaccinated for the second time with the pneumococcal vaccine, 5 years after the first vaccination. This is NOT a vaccine recommended for healthy adults but is NOT contra-indicated. Thus as part of the experimental procedure for these individuals they will:

  1. Receive the FDA approved pneumococcal vaccine
  2. Blood samples will be obtained at day 0: 2 mL, day 7 40 mL and day 28-42 one time sample of 2 mL.
  3. Blood samples will be analyzed for antibody concentration, functional activity and gene family usage.

In summary, we will study 3 groups in Part II of the study Group 6: HIV positive CD4>500, 2nd PPV Group 7: HIV positive CD4 200-500, 2nd PPV Group 8: HIV negative, 2nd PPV.

Study Type

Interventional

Enrollment (Actual)

124

Phase

  • Early Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Ohio
      • Toledo, Ohio, United States, 43614
        • The University of Toledo-Health Science Campus

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • HIV negative:
  • never immunized with PPV23
  • HIV positive:
  • need for PPV23 per standard of care

Exclusion Criteria:

  • steroid use
  • other immunosuppressive agents;
  • pregnancy
  • incapable of completing consent form

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: healthy controls
healthy individuals, HIV negative, 19-50 yrs if age, immunized with one shot of PPV23 vaccine.
Biological: PPV23
23 valent pneumococcal polysaccharide vaccine in Healthy adults.
Other Names:
  • 23 valent pneumococcal polysaccharide vaccine
Active Comparator: newly diagnosed HIV >200
Newly diagnosed HIV positive patients with CD4 count >200, immunized with one shot of PPV23 vaccine.
Biological: PPV23
23 valent pneumococcal polysaccharide vaccine in Healthy adults.
Other Names:
  • 23 valent pneumococcal polysaccharide vaccine
Active Comparator: newly diagnosed HIV <200
Newly diagnosed HIVpositive patients with CD4 count <200, immediately immunized with one shot of PPV23 vaccine.
Biological: PPV23
23 valent pneumococcal polysaccharide vaccine in Healthy adults.
Other Names:
  • 23 valent pneumococcal polysaccharide vaccine
Active Comparator: newly diagnosed HIV <200 delayed
Newly diagnosed HIV positive patients with CD4 count <200 delayed immunization with one shot of PPV23 vaccine, treated for 6-12 months with Highly Active Anti-Retroviral Therapy (HAART) first.
Biological: PPV23
23 valent pneumococcal polysaccharide vaccine in Healthy adults.
Other Names:
  • 23 valent pneumococcal polysaccharide vaccine
Active Comparator: HAART experienced HIV>200
HIV positive, on HAART treatment for 5 years, nadir CD4 count <200, but at present CD4 count is >200, immunized with one shot of PPV23 vaccine.
Biological: PPV23
23 valent pneumococcal polysaccharide vaccine in Healthy adults.
Other Names:
  • 23 valent pneumococcal polysaccharide vaccine
Active Comparator: HAART experienced HIV<200
HIVpositive, on HAART treatment for 5 years, nadir CD4 count <200, and at present CD4 count is <200, immunized with one shot of PPV23 vaccine.
Biological: PPV23
23 valent pneumococcal polysaccharide vaccine in Healthy adults.
Other Names:
  • 23 valent pneumococcal polysaccharide vaccine

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Antibody activity and response by opsonophagocytic assay (OPT) and ELISA (ug/ml)
Time Frame: Day 0 and day 30 of vaccination
Day 0 and day 30 of vaccination

Secondary Outcome Measures

Outcome Measure
Time Frame
Polysaccharide-specific B cell phenotype: percentage naive or memory B cell distribution flow cytometry
Time Frame: Day 0 and Day7 of vaccination
Day 0 and Day7 of vaccination
Flow cytometry : percentage cells expressing tumor necrosis factor receptors on surface
Time Frame: Day 0 and Day7 of vaccination
Day 0 and Day7 of vaccination

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Toledo Health Science Campus

Collaborators

National Institutes of Health (NIH)

Investigators

  • Principal Investigator: Julie MA Westerink, MD, University of Toledo-HSC

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

July 1, 2010

Primary Completion (Actual)

June 1, 2014

Study Completion (Actual)

March 1, 2015

Study Registration Dates

First Submitted

July 7, 2015

First Submitted That Met QC Criteria

August 3, 2015

First Posted (Estimate)

August 4, 2015

Study Record Updates

Last Update Posted (Estimate)

August 7, 2015

Last Update Submitted That Met QC Criteria

August 5, 2015

Last Verified

July 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HIV PPV23
  • 5R01AI081558 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pneumococcal Infection

Clinical Trials on PPV23

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe